Anthropic shares early results from Claude in six drug development partnerships

Anthropic says it has worked with six organisations (BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group) and has started drug programmes of its own, including for rare childhood forms of muscular dystrophy. The most transferable result is about paperwork, not molecules: at Enveda, Claude reviewed 1,061 pages of manufacturing documents, caught all 11 issues human reviewers had found plus seven they had missed, and cut review time by 89%, from over 25 hours to under three; it also drafted one regulatory document in four hours against about three months by hand. Partners also report lab results, such as a Generate design about 70% shorter than the standard version that let immune cells make roughly 10 times as many cancer-spotting receptors in lab tests. Anthropic says the work is mostly preclinical, so most of it has not reached testing in humans, and these are its own and its partners' reports. On Hacker News (20 top-level comments) there was no consensus, but the lean was sceptical. The largest group, including a commenter who said they were a former drug developer, argued that proposing candidate molecules is the easy part and that wet-lab work, trials and regulation are the real bottlenecks; one asked why there were so few examples. A smaller group was cautiously hopeful, and one commenter singled out the Enveda document-review result as the most interesting part. Two commenters complained that Claude's safety guardrails and a hard-to-access verification programme get in the way of legitimate biology research. Sorted take: the lesson for most businesses is the document review, not the drug design; checking long regulated records against each other is a job AI can speed up while a human still signs off.